Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naïve (TN) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting.
The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. As Ascentage Pharma returns to the ASCO Annual Meeting for the eighth consecutive year, two studies of lisaftoclax and MDM2-p53 inhibitor alrizomadlin (APG-115), key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation.
This oral presentation reported results from a multi-country, multi-center Phase Ib/II study of lisaftoclax, which as of data cutoff in April 2025, enrolled a total of 103 patients, including patients with TN or relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Findings of this study once again underscored the promising antitumor activity and manageable tolerability of lisaftoclax in myeloid malignancies. Furthermore, for the first time, this study reported responses in venetoclax-refractory patients who received lisaftoclax, thus suggesting that lisaftoclax has favorable antitumor activity and is differentiated from other drugs in the same class.
Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was accepted and granted a Priority Review designation by the Center for Drug Evaluation (CDE) of China's National Medical Product Administration (NMPA). With this submission, lisaftoclax has become the first China-developed Bcl-2 inhibitor to reach NDA submission in China, and the second Bcl-2 inhibitor with submitted NDAs anywhere in the world. At present, lisaftoclax is being evaluated in four global registrational Phase III studies in major indications such as CLL/SLL, AML, and MDS, including a US Food and Drug Administration (FDA)-cleared multi-country, registrational Phase III trial.
Patricia Kropf, MD, Principal Investigator of the study from Novant Health Cancer Institute, commented, 'In this global, multicenter study, lisaftoclax in combination with azacitidine showed promising efficacy and a tolerable safety profile for patients with treatment-naïve or R/R AML and MDS. This data supports the upcoming Phase III study using the combination therapy for this patient population. Interestingly, lisaftoclax showed the potential to overcome resistance to venetoclax in patients who failed prior treatment with venetoclax, suggesting that it might bring improved treatment outcome. We look forward to releasing more data from this study which will further validate lisaftoclax's broad therapeutic potential.'
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'In previous studies, lisaftoclax combined with azacitidine has already demonstrated significant activity in patients with various myeloid malignancies. In this oral presentation, we report the latest data from a multi-country, multicenter Phase Ib/II study that showed promising antitumor activity and good tolerability of the combination regimen in myeloid malignancies such as AML and MDS. In particular, lisaftoclax has shown therapeutic potential in venetoclax-refractory patients, making this study the first that reported a Bcl-2 inhibitor overcoming drug resistance to another Bcl-2 inhibitor, thus suggesting that lisaftoclax may bring about a breakthrough to the treatment of myeloid malignancies. For now, lisaftoclax is being evaluated in multi-countries, registrational Phase III studies in AML and MDS. We remain committed to our mission of addressing unmet clinical needs in China and around the world and plan to further accelerate our clinical programs to bring more novel therapeutics to patients as soon as possible.'
Highlights of this abstract selected for presentation at ASCO 2025 are as follows:
Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies
Abstract #: 6505
Format: Oral Presentation
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Principal Authors: Michael Francis Leahy, MBChB, Royal Perth Hospital, Australia; Shaun Fleming, MBBS(Hons), PhD, The Alfred Hospital & Australian Centre for Blood Diseases, Australia; Patricia Kropf, MD, Novant Health Cancer Institute, United States, et al.
Highlights:
Background:
AML and MDS are hematologic malignancies with poor prognoses.
Hypomethylating agents (HMAs) AZA and decitabine are approved for MDS and AML and have been shown to prolong survival in patients. However, additional treatment options that improve clinical outcomes, such as complete response (CR) and overall survival (OS), are needed.
Lisaftoclax is an investigational, orally active, small-molecule Bcl-2 inhibitor that has shown enhanced treatment responses in AML and MDS when combined with AZA in preclinical 1 and clinical 2 studies.
Efficacy results:
As of the data cutoff in April 2025, 22 of 28 venetoclax-refractory patients with R/R AML/ Mixed Phenotype Acute Leukemia (MPAL) were efficacy-evaluable, among whom, the overall response rate (ORR) was 31.8%, including 22.8%, 4.6%, and 4.6% achieving CR/CR with incomplete hematologicrecovery (CRi), partial response (PR), and the morphologic leukemia-free state (MLFS), respectively. All responsive patients had received multiple lines of therapy that included venetoclax, and most of them (71%, 5/7) harbored the TP53 mutation and had a complex chromosomal karyotype at baseline.
In 6 efficacy-evaluable patients with newly diagnosed (ND) AML/MPAL, the ORR was 83.3%, with CR/CRi and PR achieved by 33.3% and 50% of patients, respectively. In 44 efficacy-evaluable patients with R/R AML/MPAL, the ORR was 43.2%, with CR/CRi, PR, and MLFS achieved by 31.8%, 4.5%, and 6.8% of patients, respectively.
In 15 efficacy-evaluable patients with ND MDS/chronic myelomonocytic leukemia (CMML), the ORR was 80%, with CR and marrow CR (mCR) achieved by 40% and 40% of patients, respectively. In 22 efficacy-evaluable patients with R/R MDS/CMML, the ORR was 50%, with CR, mCR, and PR achieved by 27.3%, 18.2%, and 4.5% of patients, respectively.
Safety results: Lisaftoclax in combination with AZA was well tolerated, with a manageable profile. Common adverse events were mostly hematologic. Nonhematologic toxicity was uncommon. The majority of adverse events were manageable, reversible and tolerable.
Conclusions: Lisaftoclax combined with AZA showed promising antitumor activity and favorable tolerability in patients with TN or R/R myeloid malignancies. Furthermore, lisaftoclax demonstrated the ability to overcome drug resistance to venetoclax, making this the first clinical study to report a Bcl-2 inhibitor overcoming venetoclax resistance.
* Lisaftoclax (APG-2575) is an investigational compound and has not been approved by the US FDA.
Reference:
1 Zhai Y, Tang Q, Fang DD, et al. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies. Clin Cancer Res. 2023;29:183-196. https://doi.org/10.1158/1078-0432.CCR-22-0978
2 Wang H, Wei X, Jiang Q, et al. Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms. Blood 2023;142(Suppl 1):2925. https://doi.org/10.1182/blood-2023-188489
About Ascentage Pharma
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The lead asset, olverembatinib, is the first third generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph + ALL patients and SDH-deficient GIST patients.
The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777
Stephanie Carrington
ICR Healthcare
Stephanie.Carrington@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
Sean.Leous@icrhealthcare.com
+1 (646) 866-4012
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Is TJX's 5% Drop Post Q1 Earnings a Caution or Opportunity?
The TJX Companies, Inc. TJX saw its shares drop 5% following the release of its first-quarter fiscal 2026 results on May 21, 2025. This performance marks a notable underperformance compared to the Zacks Retail - Discount Stores industry, the Zacks Retail and Wholesale sector, which slipped 1% and 0.5%, respectively, and the broader S&P 500, which advanced 0.2% during the same period. The TJX Companies' Price Performance Post-Earnings The TJX Companies has delivered relatively lower stock performance compared to some other major players in the discount retail sector, such as Dollar General Corporation DG, Dollar Tree DLTR and Costco Wholesale Corporation COST. During the same period, Dollar General Corporation, Dollar Tree and Costco Wholesale Corporation posted gains of 10.2%, 6.8% and 1.9%, respectively. Notably, the pullback in TJX shares came despite the company surpassing expectations on both the top and bottom lines. Its fiscal first-quarter results exceeded the Zacks Consensus Estimate for earnings and revenue, reflecting continued strength in customer traffic and solid comparable store sales across all divisions. Interestingly, the stock was trading near record levels ahead of the earnings release. Trading at $128.12 as of June 3, TJX shares are down 5.7% from their 52-week high of $135.85, which was reached on May 20, just a day before the earnings announcement. This divergence between solid earnings performance and stock price weakness raises a critical question for investors: Is the pullback a short-term overreaction or a long-term buying opportunity? TJX's Q1 Performance: Key Takeaways The TJX Companies reported a strong start to fiscal year 2026, demonstrating solid performance across all divisions. Growth was broad-based, fueled by an increase in customer traffic in both U.S. and international markets. As a result, net sales reached $13,111 million, marking a 5% year-over-year increase, consistent on a constant currency basis. Consolidated comparable store sales rose 3%, primarily driven by higher customer transactions. However, earnings per share (EPS) were 92 cents per share, down from 93 cents reported in the year-ago quarter. Breaking down the performance by segment, comparable store sales grew 2% at Marmaxx (U.S.), 4% at HomeGoods (U.S.), 5% at TJX Canada, and 5% at TJX International (Europe and Australia). Comparable sales increased in both apparel and home categories, underscoring TJX's effective strategy and positioning the company for long-term sustainability with a focus on driving customer transactions. TJX Reaffirms Growth Outlook Amid Challenges On its last earnings call, TJX highlighted a strong start to the fiscal second quarter and reaffirmed its focus on executing the core fundamentals of its off-price retail model. Management remains confident that the company's broad and compelling assortments, coupled with a resilient business model, will continue to attract value-conscious shoppers, even amid ongoing macroeconomic challenges and tariff-related pressures. The company expects consolidated comparable store sales growth of 2% to 3% for the fiscal second quarter. Quarterly EPS are projected to range between 97 cents and $1.00, indicating a 1% to 4% increase compared to 96 cents in the prior year's period. For the full fiscal year 2026, TJX anticipates comparable store sales growth of 2% to 3%, consolidated sales to be in the range of $58.1 billion to $58.6 billion, up 3% to 4% with EPS forecasted between $4.34 and $4.43, an increase of 2% to 4% from the previous year's $4.26. The TJX Companies' Strategic Strengths TJX Companies remains upbeat about its long-term prospects, grounded in a strong business model and a proven ability to adapt through various retail and economic cycles. The company credits its resilience to the flexibility of its off-price model, the experience of its leadership team, and a well-established global buying network that taps into a wide range of vendors worldwide. At the heart of TJX's strategy is its value proposition, delivering a compelling mix of brand, fashion, quality, and price, which continues to attract a broad and diverse customer base. This broad appeal is supported by a carefully curated mix of brands that sustain steady traffic. Backed by a flexible, global buying and supply chain model and a unique treasure-hunt shopping experience, it remains well-equipped to adapt to changing consumer preferences and capture market share in both stable and challenging economic conditions. TJX has also benefited from solid growth in both its physical stores and e-commerce channels. The company is rapidly expanding its footprint in the United States, Europe, Canada, and Australia. In the first quarter of fiscal 2026 alone, TJX added 36 new stores, ending the quarter with a total of 5,121 locations. Further, with an increasing number of consumers resorting to online shopping, The TJX Companies has undertaken several initiatives to boost online sales and strengthen its e-commerce business. Is TJX Stock's Discounted Valuation Good? The TJX Companies is currently trading at a notable discount compared to its industry peers, making it an appealing option for value-focused investors. As of now, TJX trades at a forward 12-month price-to-earnings (P/E) ratio of 27.75X, which is significantly lower than the industry average of 34.17X. While its valuation is lower than that of Costco Wholesale Corporation, which trades at a significantly higher 54.42X, it remains above other discount retail peers such as Dollar General Corporation and Dollar Tree, which have P/E ratios of 19.48X and 17.89X, respectively. TJX P/E Ratio (Forward 12 Months) The TJX Companies is also trading well above its 50-day and 200-day moving averages, an important bullish technical indicator. This breakout is not just technical but reflects growing market confidence in its growth story. TJX Companies: Navigating Cost Pressures and Global Risks Despite its strengths, TJX faces several challenges that could impact its near-term performance. Rising operating costs, driven by inflationary pressures and wage increases, may put pressure on margins despite ongoing efforts to manage expenses. Additionally, continued trade tensions and tariffs on imports from China and other countries remain a concern, while foreign exchange headwinds could further weigh on profitability. One of the key near-term risks for TJX is the impact of tariffs on both direct and indirect imports into the U.S. Management expects these pressures to weigh on fiscal second-quarter performance, with gross margin projected to decline by 40 basis points (bps) year over year to 30%. Despite mitigation strategies like pricing adjustments and sourcing shifts, the company forecasts a full-year gross margin contraction of 10 to 20 bps, which could strain profitability even if sales remain strong. Additionally, TJX's international operations make it vulnerable to currency fluctuations. Management anticipates foreign exchange headwinds will reduce pretax profit margin by 10 to 20 basis points in fiscal 2026, presenting further risks to overall performance. Downward Estimate Movement of TJX's Earnings Reflecting cautious sentiment around The TJX Companies, the Zacks Consensus Estimate for EPS has seen downward revisions. Over the past 30 days, the consensus estimate has declined 2 cents to $1.00 for the current quarter and a cent to $4.46 for the fiscal year, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Investor Takeaway for TJX Following the post-earnings dip, The TJX Companies presents a mixed picture for investors. While the company delivered better-than-expected results in the fiscal first quarter, driven by solid customer traffic and broad-based sales growth, external headwinds continue to weigh on sentiment. Inflationary cost pressures, rising wages, tariffs and currency fluctuations are expected to pressure margins in the near term. Additionally, recent downward revisions in earnings estimates reflect growing investor caution. That said, TJX's resilient off-price model, strong global footprint, and consistent execution provide a solid foundation for long-term growth. With shares trading at a reasonable valuation relative to peers, investors may consider holding the stock as the company navigates short-term challenges. As macro conditions stabilize and cost pressures ease, TJX could be well-positioned to regain momentum. The TJX Companies carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The TJX Companies, Inc. (TJX): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report Dollar Tree, Inc. (DLTR): Free Stock Analysis Report Costco Wholesale Corporation (COST): Free Stock Analysis Report
Globe and Mail
37 minutes ago
- Globe and Mail
Bitcoin Hedge Theory Meets a Harsh Boardroom Reality
The Bitcoin (CRYPTO: BTC) whitepaper compared the cryptocurrency to physical gold in 2008. 17 years later, the cryptocurrency seems ready to take on a more gold-like role in the global economy. But it's not all good news. A couple of tech giants have recently demonstrated that the traditional business world still lags behind in embracing Bitcoin as a long-term general asset. Here's what crypto investors need to know about this development. How Bitcoin earned its Wall Street stripes The Bitcoin platform has earned some Street cred in recent years. Large-scale investors have access to exchange-traded funds (ETFs) based on spot Bitcoin prices. These spot Bitcoin funds have nearly $121 billion of digital assets under management in June 2025. Some of the most significant buys of these ETFs come from old-school financial giants such as Goldman Sachs (NYSE: GS) and Morgan Stanley (NYSE: MS). Massive companies like Tesla (NASDAQ: TSLA) and Block (NYSE: XYZ) have converted hundreds of millions of dollars into Bitcoin. Running even further ahead of the crypto trend, Strategy (NASDAQ: MSTR) is more of a Bitcoin investment vehicle than a software developer nowadays. The company formerly known as Microstrategy has built a $61.7 billion Bitcoin portfolio with mostly borrowed money and shareholder funds. The Trump administration included crypto support in its campaign messages, and is indeed taking some industry-friendly steps already. There is now an official Strategic Bitcoin Reserve and a smaller Digital Asset Stockpile for other cryptocurrencies. Also, this iteration of the Securities and Exchange Commission looks ready to approve crypto-investing policies that the previous group kept kicking down the road. These political twists have to be good news for Bitcoin owners. Bitcoin-based investments used to be pure high-risk ideas, with sky-high beta values indicating massive volatility. That's no longer the case. Last year's ETF introductions and Bitcoin halving event threw some cold water on the cryptocurrency's volatility. Recently, Bitcoin ETFs have explored negative beta values, suggesting that this asset often moves in the opposite direction of the American stock market. That's taking the hedging thesis to a new extreme. Low beta values signify below-average price swings, while negative ones belong to investments that often move in direct opposition to the stock market. Long story short, there are many reasons to treat Bitcoin as an effective market hedge nowadays. The largest and oldest cryptocurrency can counterbalance many quirks in the American and global economy. Tech giants face the crypto conversation Inspired by these newfound stability qualities, activist investors have been asking some of the world's largest tech titans to buy some Bitcoin. Actually, not even that -- two different groups asked Microsoft (NASDAQ: MSFT) and Meta Platforms (NASDAQ: META) to just look into the idea. The proxy statements for both companies' annual shareholder meetings asked the board of directors to simply assess whether some Bitcoin exposure would be good for shareholders. As usual, Meta and Microsoft opposed these proposals. Microsoft's board recommended shareholders to vote against the measure, since the company already considers every cash management option -- including Bitcoin. Meta's board offered the same recommendation, citing its own comprehensive review of every reasonable idea. "While we are not opining on the merits of cryptocurrency investments compared to other assets, we believe the requested assessment is unnecessary given our existing processes to manage our corporate treasury," the recommendation ended. The votes are in -- and they're brutal Putting these Bitcoin proposals on the proxy statements didn't exactly change the game. The policy assessment requests got almost no support from shareholders. Microsoft's vote results were published in December 2024. Every shareholder proposal fell short of approval. The top performers got more than 30% approval ratings, but the Bitcoin topic fell between the cracks with just 0.55% "yea" votes. It was Meta's turn to vote on this stuff last Wednesday. A few proposals got the thumbs-up vote from at least 20% of shareholders, but the Bitcoin assessment was barely there. Approval rating: 0.08%. I mean, that's barely a shadow of a forgotten thought experiment. Reading between the voting lines At first glance, the overwhelming downvotes look like a total condemnation of Bitcoin as a hedging instrument. Fractions of a single percent simply don't show any real support for that idea. Take your Bitcoin and go home, dear activist investors. But there's more nuance to this situation. The negative company board recommendations came with careful language explaining that they're already thinking about this stuff anyway. Therefore, some investors may simply be satisfied with the ordinary review of financial management options -- if Bitcoin ever becomes a no-brainer wealth management holding, the strategic committees of the world's largest tech giants will surely figure it out and take action. At the same time, there's some truth to the anti-Bitcoin sentiment seen in these lopsided votes. The vast majority of Microsoft and Meta Platforms shares are held by institutional investors, led by ETF managers and retirement fund portfolios. Getting the first hint of Bitcoin investment support from those groups should drive Bitcoin prices dramatically higher in a hurry -- but the mega-investors aren't ready to make that commitment yet. All in all, I find the lack of investor support surprising but the proposals may have served a worthwhile purpose anyhow. Just asking people to think about Bitcoin as a long-term investment could have positive long-term effects. In this early stage, lots of investors just haven't taken Bitcoin seriously yet. If each vote proposal got just one more financial heavyweight to start thinking in those terms, I'd say it was worth the mountains of proxy-filing paperwork. Should you invest $1,000 in Bitcoin right now? Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of June 2, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Anders Bylund has positions in Bitcoin. The Motley Fool has positions in and recommends Bitcoin, Block, Goldman Sachs Group, Meta Platforms, Microsoft, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
38 minutes ago
- Globe and Mail
Tether Just Made Twenty One Capital a Bitcoin Powerhouse
$3.9 billion worth of Bitcoin didn't just disappear into cold storage. It went straight into Jack Mallers' hands — or more precisely, his new venture, Twenty One Capital. In just a few days, the platform has gone from under-the-radar to the third-largest corporate holder of Bitcoin globally, now trailing only Strategy (MSTR) and MARA Holdings (MARA). Confident Investing Starts Here: Tether, alongside its sister firm Bitfinex, moved 37,229 BTC across several tracked transactions. Tether's CEO Paolo Ardoino confirmed the activity in real-time, documenting the flow on-chain. Some of the Bitcoin was designated for SoftBank's investment in the venture; the rest supported convertible equity agreements. This wasn't just about stacking sats — it was about cementing a new financial architecture with Bitcoin as the foundation. Build the Future on Bitcoin Rails Twenty One Capital, helmed by Strike founder Mallers, isn't trying to be just another crypto company. It's aiming to rebuild capital markets infrastructure entirely on Bitcoin rails. Lending, custody, asset issuance — all native to Bitcoin. That's the pitch. And now, with $3.9 billion backing it and a planned SPAC merger with Cantor Fitzgerald's Cantor Equity Partners, the runway is wide open. The company is already valued at $3.6 billion before a single product goes mainstream. Back Bitcoin as Infrastructure, Not Just an Asset What makes this move more than just another institutional play is its intent: Tether and Bitfinex aren't simply investing in Bitcoin as an asset — they're backing a future where Bitcoin becomes the infrastructure for financial markets. This shift away from proof-of-stake chains and hybrid models toward pure Bitcoin rails could show that major crypto players are starting to move their money away from speculative tokens and into building real financial systems directly on Bitcoin. While Strategy's Michael Saylor stands firm against on-chain proof-of-reserves, citing security risks, Mallers and company are moving billions in full view. Transparency isn't optional — it's the foundation. Bitcoin Isn't Just a Store of Value The implications ripple far wider than a single firm's wallet size. With these transactions, Twenty One Capital is positioning itself as the institutional layer Bitcoin has long lacked. It's a rebuttal to the notion that serious financial infrastructure can't be built on Bitcoin. And it's a declaration that Bitcoin isn't just a store of value — it's the backbone of the next financial system. This also sets up a showdown of philosophies. While some players hoard BTC and keep their moves private, Mallers is building a fortress in the open. The capital is public. The intent is aggressive. And the message is clear: Bitcoin doesn't need Wall Street's blessing. It needs builders who speak its language. At the time of writing, Bitcoin is sitting at $106,649.65.
